Literature DB >> 26386776

Characterization of Staphylococcus aureus infections in children with Down syndrome.

Jeffrey N Johnston1, Sheldon L Kaplan1, Edward O Mason1, Kristina G Hulten2.   

Abstract

Staphylococcus aureus infections in the Down syndrome (DS) population have not been well characterized. This study determined clinical and molecular characteristics of S. aureus infections in children with DS followed at Texas Children's Hospital (TCH), from 2001 to 2011. Patients were retrospectively identified from an ongoing S. aureus surveillance study. Medical records were reviewed. Isolates were characterized by antimicrobial susceptibility, pulsed-field gel electrophoresis patterns, and detection of PVL genes (pvl), mupA (high-level mupirocin resistance gene), smr (chlorhexidine resistance conferring gene), and Staphylococcal Chromosomal Cassette mec (SCCmec) type. Twenty-six patients with DS had a total of 34 S. aureus infections (8 recurrent); 61% were MRSA. DS patients represented 16.8 per 10,000 community onset S. aureus infections seen at TCH. Among 26 initial infections 17 were skin and soft tissue (SSTI), 7 were outer or middle ear and 2 were invasive infections. Seventeen patients were hospitalized. Thirteen (65%) of 20 available isolates were USA300, 14 were pvl+, 5 were mupA+, and 8 were smr+. Five of 8 (63%) recurrent infections were ear infections. All 4 recurrent ear isolates available for study were smr+, ciprofloxacin non-susceptible and treated with ciprofloxacin otic drops. S. aureus infections among patients with DS were similar in presentation to other patient groups, except for a greater proportion being associated with ear infections. Seventy percent of ear fluid isolates carried antiseptic and fluoroquinolone resistance genes. A study of a greater number of DS patients is warranted to further explore these findings.
Copyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Down syndrome; Pediatric; Staphylococcus aureus; mupA; smr

Mesh:

Substances:

Year:  2015        PMID: 26386776     DOI: 10.1016/j.jiac.2015.08.002

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

1.  Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.

Authors:  Xiao-Fei Kong; Lisa Worley; Darawan Rinchai; Vincent Bondet; Puthen Veettil Jithesh; Marie Goulet; Emilie Nonnotte; Anne Sophie Rebillat; Martine Conte; Clotilde Mircher; Nicolas Gürtler; Luyan Liu; Mélanie Migaud; Mohammed Elanbari; Tanwir Habib; Cindy S Ma; Jacinta Bustamante; Laurent Abel; Aimé Ravel; Stanislas Lyonnet; Arnold Munnich; Darragh Duffy; Damien Chaussabel; Jean-Laurent Casanova; Stuart G Tangye; Stéphanie Boisson-Dupuis; Anne Puel
Journal:  J Clin Immunol       Date:  2020-06-22       Impact factor: 8.317

2.  Polydatin reduces Staphylococcus aureus lipoteichoic acid-induced injury by attenuating reactive oxygen species generation and TLR2-NFκB signalling.

Authors:  Gan Zhao; Kangfeng Jiang; Haichong Wu; Changwei Qiu; Ganzhen Deng; Xiuli Peng
Journal:  J Cell Mol Med       Date:  2017-05-19       Impact factor: 5.310

Review 3.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.